Cannabics Pharmaceuticals (OTCQB:CNBX) is taking a unique approach for treating different types of cancers with its drug-screening tools and artificial intelligence (AI) platform to develop cannabinoid-based therapies that are more specific to a patient.

Although the company is publicly traded in the US, Cannabics Pharmaceuticals’ research and development (R&D) is based in Israel and licensed by the country’s Ministry of Health to perform clinical research on various combinations of cannabinoids and how they react with different types of cancer.

In an interview with the Investing News Network (INN), Eyal Barad, CEO and co-founder of Cannabics Pharmaceuticals, said that, when the company conducted its first pre-clinical study in an Israel-based university five years ago, it found that different combinations of cannabinoids have effects on “different cancers and different people.”

Learn how to invest in life science and medical stocks

Read your free starter guide to investing in life science

“When we found the optimal combination of cannabinoids, we were able to cause the cancer to commit suicide and […] the healthy cells were unaffected,” he explained.

Barad said that, through its lab, the company has been “collecting a lot of data” to provide a diagnostic product “for people to be able to personalize cannabinoid regime treatments.” He added that Cannabics Pharmaceuticals is also hoping to lead its own drug discovery or partner with other firms to find specific indications or target cancers with “specific combinations of cannabinoids” through its big-data platform.

When asked about how the company uses AI to develop cannabinoid-based therapies, Barad explained that, because there are so many different types of cancers and cannabis strains, when the cannabinoid compound of a certain strain is analyzed and applied to cancer cells, a picture is taken with a microscope and then analyzed for approximately 8,000 different parameters to “see how it’s affecting the cell.”

He explained, “all of that is translated into data, which we then need to make sense of to understand why certain [cannabinoid strains] are affecting certain cancers in what way.”

The company’s lab has a variety of tools that allow for miniaturization and automation of a wide range of biological assays. The automated system is made with a high-content screening platform, which analyzes cellular images and is designed for “quantitative microscopy.”

According to the company, readouts from these tools provide it with a deeper understanding of the effects of its cannabinoids on proliferation inhibition, apoptosis induction, angiogenesis and, of course, toxicity on cancer cells.

Meanwhile, Cannabics Pharmaceuticals’ high-throughput screening allows the company to test a variety of compounds on cancerous cell lines and tissues, allowing it to measure the “therapeutics effects” of those composites.

While the company is largely focused on treating different types of cancers, Barad said the company has “started to realize” that its platform “can be very powerful [and] can be used for a lot of different things.”

Case in point, in early February, Cannabics Pharmaceuticals and Wize Pharma (OTCQB:WIZP) formed a joint venture to develop cannabinoid-based formulations to treat a range of eye diseases.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!

“We [will] provide our lab, our license [and] our expertise in cannabinoids, and [Wize Pharma will] provide [eye expertise],” Barad told INN. “Cannabinoids have an anti-inflammatory effect and [for] various eye disorders, that is a major cognitive.”

Barad further explained that the company’s plan will be to develop products for the eye that “alleviate some of those discomforts,” and said that the eye market is a “huge market.”

He noted, “we feel that cannabinoids can have various advantages versus what’s going on with steroids in the eye market, so that’s what we’re planning on doing.”

Although there are still regulation challenges surrounding cannabis in the US at a federal level, Barad said the company is able to continue moving forward in Israel with R&D thanks to having a license in the country. That said, he explained that the “big market” is in the US, and, with over 33 states having a cannabis regime in the country, it’s only a matter of time until legitimacy reaches the space in the US.

Barad said that the eventual plan will be to bring its solutions to US patients with the hope of providing informative data before cannabis becomes federally legal.

“We hope to be able to add some additional value and data for patients before that,” he said.

Shares of Cannabics Pharmaceuticals were priced at US$0.37 as of market close on Monday (March 25). Year-to-date, the stock has increased 15 percent from US$0.32 on January 2.

Don’t forget to follow @INN_LifeScience for real-time updates!

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less